Sign in to fuzzto save your conversations, follow your research and come back anytime.

‌

‌
‌

‌
‌
‌

‌
‌

‌

‌
‌
‌
‌
‌
‌
‌

‌
‌
‌
‌
‌
‌

Anupam Rasayan Stock Price - ₹1,240.20 | Chemicals | askfuzz

A

Anupam Rasayan

ANURAS•

NSE

BSE

SectorChemicals

‌
‌
‌

₹1,240.20

+₹134.50(12.16%)•Past Year

Loading chart…

‌
‌
‌

‌
‌
‌

In the news

Anupam Rasayan Q1 profit up 6% to ₹512 cr, revenue jumps 35%

Anupam Rasayan Q1 profit up 6% to ₹512 cr, revenue jumps 35%

Anupam Rasayan launches ₹829 cr open offer for 26% Bliss GVS stake

Anupam Rasayan launches ₹829 cr open offer for 26% Bliss GVS stake

Anupam Rasayan signs $300M LoI with BASQUEVOLT for battery chemicals

Anupam Rasayan signs $300M LoI with BASQUEVOLT for battery chemicals

Anupam Rasayan achieves global ETFA milestone, stock surges

Anupam Rasayan achieves global ETFA milestone, stock surges

Anupam Rasayan acquires 43.3-48.2% stake in Bliss GVS Pharma

Anupam Rasayan acquires 43.3-48.2% stake in Bliss GVS Pharma

Major Stock Developments: Acquisitions, FDA Inspection, OFS

Major Stock Developments: Acquisitions, FDA Inspection, OFS

Stocks to Watch Today: NTPC, Eicher Motors, Paytm Lead Q4 Results

Stocks to Watch Today: NTPC, Eicher Motors, Paytm Lead Q4 Results

Anupam Rasayan Acquires 43.3% Stake in Bliss GVS Pharma for ₹1,369 Cr

Anupam Rasayan Acquires 43.3% Stake in Bliss GVS Pharma for ₹1,369 Cr

Anupam Rasayan acquires 43.30% stake in Bliss GVS Pharma for ₹1,369 cr

Anupam Rasayan acquires 43.30% stake in Bliss GVS Pharma for ₹1,369 cr

Anupam Rasayan Q3 profit rises 12% to ₹61 cr on higher revenue

Anupam Rasayan Q3 profit rises 12% to ₹61 cr on higher revenue

The Quarter story

The two most recent quarterly results, compared side-by-side.

Anupam Rasayan delivers strong top-line and margin expansion with portfolio growth, while rising finance costs and standalone profit dips require monitoring.

Consolidated EBITDA grows from ₹1,292 Cr to ₹1,749 Cr from Q1 FY26 to Q1 FY27 — robust profitability.

Finance cost rises from ₹357 Cr to ₹421 Cr from Q1 FY26 to Q1 FY27 — higher debt servicing burden.

EBITDA margin rises from 26% to 34% over five quarters — strong pricing power.

Standalone revenue falls from ₹5,956 Cr in Q2 FY26 to ₹3,349 Cr in Q1 FY27 — top-line pressure.

Consolidated revenue climbs from ₹4,907 Cr to ₹6,675 Cr from Q1 FY26 to Q1 FY27 — sustained top-line growth.

Gross profit drops from ₹2,571 Cr in Q2 FY26 to ₹1,747 Cr in Q3 FY26 — volume or mix pressure.

Product portfolio expands from 80 to 125 items by Q1 FY27 — aggressive portfolio growth.

Standalone PAT eases from ₹479 Cr in Q3 FY26 to ₹320 Cr in Q1 FY27 — profit contraction.

Other expenses fall from ₹974 Cr to ₹687 Cr over the period — improved overhead control.

Material costs swing from ₹4,743 Cr in Q2 FY26 to ₹1,386 Cr in Q1 FY27 — lower input spend but watch for demand signals.